CTN-0046-A-1: Site Influences on Treatment Effects – Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant-Dependent Outcome

November 29, 2021 /

Dennis McCarty, PhD
Lead Investigator
Professor, Department of Public Health and Preventive Medicine
Oregon Health & Science University
mccartyd@ohsu.edu

Site variations in study outcomes are apparent in clinical trials conducted within the National Drug Abuse Treatment Clinical Trials Network (CTN).  Systematic and standardized collection of organizational and workforce variables may help elucidate site variations and increase the CTN’s understanding of patient outcomes in protocols.  The Smoking-Cessation and Stimulant Treatment (CTN-0046) will be used to assess the influence of organizational and workforce characteristics on trial operations (e.g., rates of participant recruitment and follow-up) and patient outcomes (e.g., reductions in drug use).  This study will build on the analysis of organizational and workforce data in the Baseline Protocol (CTN-0008) and the collection of pre-implementation site data for STAGE-12 (CTN-0031-A-3).  The study’s specific aim is the assessment of associations between site organizational and practitioner variables and site differences in clinical trial outcomes.

Primary Findings

Attitudes and social norms were significantly correlated with one another as were attitudes and goal commitment and social norms and goal commitment. The results from this preliminary investigation indicate that CTPs differ across several workforce and organizational characteristics.

    Node Involvement

    Lead Node(s):

  • Western States Node

    • All Participating Nodes:

  • Western States Node